Experiment Number: 05121-08 P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Test Type: CHRONIC **Test Compound:** Scopolamine hydrobromide trihydrate Route: GAVAGE Species/Strain: Mouse/B6C3F1 C Number: C03098C **Lock Date:** 05/13/1992 **Cage Range:** ΑII **Date Range:** ΑII **Reasons For Removal:** ΑII **Removal Date Range:** ΑII

ΑII

Both

03/13/1995

Treatment Groups:

PWG Approval Date

Study Gender:

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:54

First Dose M/F: NA / NA

Lab: BAT

CAS Number: 6533-68-2

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:54

First Dose M/F: NA / NA

B6C3F1 Mouse MALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36I
Disposition Summary				
Animals Initially In Study	60	50	60	50
Scheduled Sacrifice	10		10	
Early Deaths				
Natural Death	1	2	2	1
Survivors				
Moribund Sacrifice		11		5
Natural Death		9		7
Terminal Sacrifice	49	28	48	37
Animals Examined Microscopically	60	50	60	50
ALIMENTARY SYSTEM				
Esophagus	(60)	(50)	(60)	(50)
Gallbladder	(60)	(50)	(58)	(49)
Intestine Large, Cecum	(60)	(50)	(59)	(50)
Intestine Large, Colon	(60)	(50)	(60)	(49)
Intestine Large, Rectum	(59)	(50)	(59)	(50)
Intestine Small, Duodenum	(60)	(50)	(59)	(50)
Carcinoma				1 (2%)
Intestine Small, Ileum	(59)	(50)	(60)	(49)
Lymphoma Malignant Mixed				1 (2%)
Intestine Small, Jejunum	(60)	(50)	(60)	(49)
Carcinoma				1 (2%)
Hemangiosarcoma		2 (4%)		
Lymphoma Malignant Lymphocytic		2 (4%)		
Lymphoma Malignant Mixed		2 (4%)		5 (10%)
Liver	(60)	(50)	(60)	(50)
Carcinoma, Metastatic, Stomach, Glandular				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:54

First Dose M/F: NA / NA

Lab: BAT

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

B6C3F1 Mouse MALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Hemangiosarcoma		1 (2%)		
Hepatocellular Adenoma	3 (5%)	7 (14%)		7 (14%)
Hepatocellular Adenoma, Multiple				1 (2%)
Hepatocellular Carcinoma	2 (3%)	7 (14%)		4 (8%)
Hepatocellular Carcinoma, Multiple			1 (2%)	1 (2%)
Histiocytic Sarcoma		2 (4%)		1 (2%)
Lymphoma Malignant Lymphocytic	1 (2%)	2 (4%)	1 (2%)	3 (6%)
Lymphoma Malignant Mixed		3 (6%)		3 (6%)
Lymphoma Malignant Undifferentiated Cell Type		1 (2%)		
Mesentery	(1)	(5)	(0)	(1)
Lymphoma Malignant Lymphocytic		1 (20%)		
Pancreas	(60)	(50)	(60)	(50)
Lymphoma Malignant Lymphocytic	1 (2%)	1 (2%)		
Lymphoma Malignant Mixed				1 (2%)
Lymphoma Malignant Undifferentiated Cell Type		1 (2%)		
Salivary Glands	(60)	(50)	(60)	(50)
Lymphoma Malignant Mixed				1 (2%)
Stomach, Forestomach	(60)	(50)	(60)	(50)
Squamous Cell Papilloma		1 (2%)	2 (3%)	1 (2%)
Stomach, Glandular	(60)	(50)	(60)	(50)
Carcinoma		1 (2%)		1 (2%)
Tongue	(1)	(0)	(0)	(1)
Tooth	(2)	(3)	(0)	(7)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(60)	(50)	(60)	(50)
Heart	(60)	(50)	(60)	(50)
Carcinoma, Metastatic, Lung		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

First Dose M/F: NA / NA Lab: BAT

Date Report Requested: 10/16/2014

Time Report Requested: 06:24:54

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

B6C3F1 Mouse MALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Carcinoma, Metastatic, Lung		1 (2%)		
Lymphoma Malignant Lymphocytic			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(60)	(50)	(60)	(50)
Capsule, Adenoma				1 (2%)
Adrenal Medulla	(60)	(50)	(59)	(50)
Pheochromocytoma Benign	1 (2%)			
Islets, Pancreatic	(60)	(50)	(59)	(50)
Adenoma		1 (2%)		1 (2%)
Parathyroid Gland	(49)	(50)	(54)	(47)
Pituitary Gland	(58)	(47)	(38)	(47)
Pars Distalis, Adenoma				3 (6%)
Thyroid Gland	(60)	(50)	(60)	(50)
Follicular Cel, Adenoma		1 (2%)	2 (3%)	
GENERAL BODY SYSTEM				
Tissue NOS	(0)	(0)	(0)	(1)
Sarcoma				1 (100%)
GENITAL SYSTEM				
Epididymis	(60)	(50)	(60)	(50)
Histiocytic Sarcoma				1 (2%)
Lymphoma Malignant Lymphocytic		2 (4%)		3 (6%)
Lymphoma Malignant Mixed				1 (2%)
Preputial Gland	(60)	(50)	(59)	(50)
Prostate	(60)	(50)	(60)	(50)
Adenoma		1 (2%)		
Lymphoma Malignant Lymphocytic		1 (2%)		3 (6%)
Seminal Vesicle	(60)	(50)	(60)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:54

First Dose M/F: NA / NA

B6C3F1 Mouse MALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Lymphoma Malignant Lymphocytic		1 (2%)		3 (6%)
Testes	(60)	(50)	(60)	(50)
Histiocytic Sarcoma				1 (2%)
Interstit Cell, Adenoma	2 (3%)			
HEMATOPOIETIC SYSTEM				
Bone Marrow	(60)	(50)	(60)	(50)
Hemangiosarcoma, Metastatic, Spleen		1 (2%)		
Histiocytic Sarcoma		1 (2%)		1 (2%)
Lymphoma Malignant Lymphocytic				1 (2%)
Lymphoma Malignant Mixed				2 (4%)
Lymphoma Malignant Undifferentiated Cell Type		1 (2%)		
Lymph Node	(0)	(4)	(0)	(4)
Hepatocellular Carcinoma, Metastatic, Liver		1 (25%)		
Lymphoma Malignant Lymphocytic		1 (25%)		2 (50%)
Lymphoma Malignant Mixed		1 (25%)		1 (25%)
Lymphoma Malignant Undifferentiated Cell Type		1 (25%)		
Pancreatic, Lymphoma Malignant Mixed				1 (25%)
Renal, Lymphoma Malignant Lymphocytic		1 (25%)		
Lymph Node, Bronchial	(0)	(0)	(3)	(0)
Lymph Node, Mandibular	(60)	(48)	(59)	(47)
Lymphoma Malignant Lymphocytic		2 (4%)		4 (9%)
Lymphoma Malignant Mixed		1 (2%)		1 (2%)
Lymph Node, Mediastinal	(1)	(7)	(0)	(3)
Carcinoma, Metastatic, Lung		1 (14%)		
Lymphoma Malignant Lymphocytic	1 (100%)	2 (29%)		2 (67%)
Lymphoma Malignant Mixed		3 (43%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

First Dose M/F: NA / NA Lab: BAT

Date Report Requested: 10/16/2014

Time Report Requested: 06:24:54

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

B6C3F1 Mouse MALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Lymphoma Malignant Undifferentiated Cell Type		1 (14%)	,	
Lymph Node, Mesenteric	(60)	(49)	(59)	(46)
Carcinoma, Metastatic, Stomach, Glandular				1 (2%)
Lymphoma Malignant Lymphocytic	1 (2%)	2 (4%)		2 (4%)
Lymphoma Malignant Mixed		5 (10%)		6 (13%)
Lymphoma Malignant Undifferentiated Cell Type		1 (2%)		
Spleen	(60)	(50)	(60)	(50)
Hemangioma		1 (2%)		
Hemangiosarcoma	1 (2%)	2 (4%)		1 (2%)
Histiocytic Sarcoma		1 (2%)		
Lymphoma Malignant Lymphocytic	1 (2%)	2 (4%)	1 (2%)	3 (6%)
Lymphoma Malignant Mixed		3 (6%)		3 (6%)
Lymphoma Malignant Undifferentiated Cell Type		1 (2%)		
Thymus	(55)	(34)	(55)	(38)
Lymphoma Malignant Lymphocytic	1 (2%)	2 (6%)	1 (2%)	1 (3%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(1)	(0)	(0)	(0)
Skin	(60)	(48)	(60)	(50)
Subcut Tiss, Lymphoma Malignant Lymphocytic		2 (4%)		
Subcut Tiss, Sarcoma	1 (2%)			
MUSCULOSKELETAL SYSTEM				
Bone	(60)	(50)	(60)	(50)
Skeletal Muscle	(0)	(0)	(0)	(1)
Lymphoma Malignant Lymphocytic				1 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:54

First Dose M/F: NA / NA

Lab: BAT

B6C3F1 Mouse MALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36N
NERVOUS SYSTEM				
Brain	(60)	(50)	(60)	(50)
Carcinoma, Metastatic, Lung		1 (2%)		
Peripheral Nerve	(0)	(1)	(0)	(1)
Spinal Cord	(0)	(1)	(0)	(1)
RESPIRATORY SYSTEM				
Lung	(60)	(50)	(60)	(50)
Alveolar/Bronchiolar Adenoma	8 (13%)	7 (14%)	7 (12%)	9 (18%)
Alveolar/Bronchiolar Adenoma, Multiple		3 (6%)		2 (4%)
Alveolar/Bronchiolar Carcinoma	2 (3%)	7 (14%)		7 (14%)
Alveolar/Bronchiolar Carcinoma, Multiple				1 (2%)
Carcinoma, Metastatic, Harderian Gland		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver		2 (4%)	1 (2%)	1 (2%)
Lymphoma Malignant Lymphocytic		2 (4%)	1 (2%)	1 (2%)
Lymphoma Malignant Mixed				2 (4%)
Mediastinum, Lymphoma Malignant Lymphocytic		1 (2%)		
Nose	(60)	(50)	(60)	(50)
Trachea	(60)	(50)	(60)	(50)
SPECIAL SENSES SYSTEM				
Ear	(0)	(2)	(0)	(0)
Histiocytic Sarcoma		1 (50%)		
Eye	(0)	(1)	(0)	(3)
Harderian Gland	(26)	(24)	(26)	(23)
Adenoma	2 (8%)	2 (8%)		4 (17%)
Carcinoma		1 (4%)		

URINARY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:54

First Dose M/F: NA / NA

B6C3F1 Mouse MALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Kidney	(60)	(50)	(60)	(50)
Carcinoma, Metastatic, Lung		1 (2%)		
Lymphoma Malignant Lymphocytic		1 (2%)	1 (2%)	1 (2%)
Lymphoma Malignant Mixed		2 (4%)		2 (4%)
Renal Tubule, Adenoma				1 (2%)
Urinary Bladder	(60)	(50)	(59)	(49)
Lymphoma Malignant Mixed				1 (2%)
SYSTEMIC LESIONS				
Multiple Organ	*(60)	*(50)	*(60)	*(50)
Histiocytic Sarcoma		3 (6%)		1 (2%)
Lymphoma Malignant Lymphocytic	1 (2%)	5 (10%)	1 (2%)	4 (8%)
Lymphoma Malignant Mixed		5 (10%)		8 (16%)
Lymphoma Malignant Undifferentiated Cell Type		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:54

First Dose M/F: NA / NA

Lab: BAT

B6C3F1 Mouse MALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Tumor Summary for MALE				
Total Animals with Primary Neoplasms (b)	19	38	12	40
Total Primary Neoplasms	23	59	13	61
Total Animals with Benign Neoplasms	14	21	10	24
Total Benign Neoplasms	16	24	11	30
Total Animals with Malignant Neoplasms	6	30	2	29
Total Malignant Neoplasms	7	35	2	31
Total Animals with Metastatic Neoplasms		6	1	2
Total Metastatic Neoplasms		9	1	3
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain - Benign or Malignant				

END OF MALE DATA

Total Uncertain Neoplasms

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:54

First Dose M/F: NA / NA

B6C3F1 Mouse FEMALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Disposition Summary				
Animals Initially In Study	60	50	60	50
Scheduled Sacrifice	10		10	
Early Deaths				
Dosing Accident			1	
Moribund Sacrifice	2	4	2	3
Natural Death	1	1	3	2
Survivors				
Dosing Accident				1
Moribund Sacrifice		14		13
Natural Death		11		12
Terminal Sacrifice	47	20	44	19
Animals Examined Microscopically	60	50	60	50
ALIMENTARY SYSTEM				
Esophagus	(59)	(50)	(60)	(50)
Gallbladder	(60)	(50)	(60)	(49)
Lymphoma Malignant Lymphocytic				1 (2%)
Lymphoma Malignant Mixed				2 (4%)
Intestine Large, Cecum	(60)	(49)	(60)	(48)
Lymphoma Malignant Mixed				1 (2%)
Intestine Large, Colon	(60)	(49)	(60)	(50)
Intestine Large, Rectum	(60)	(50)	(60)	(49)
Intestine Small, Duodenum	(60)	(50)	(60)	(50)
Intestine Small, Ileum	(57)	(49)	(60)	(50)
Intestine Small, Jejunum	(60)	(50)	(60)	(49)
Histiocytic Sarcoma		2 (4%)	•	•
Lymphoma Malignant Mixed		5 (10%)	3 (5%)	4 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Lab: BAT

Date Report Requested: 10/16/2014

Time Report Requested: 06:24:54

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Sarcoma, Metastatic, Skin Liver Hepatocellular Adenoma Hepatocellular Adenoma, Multiple Hepatocellular Carcinoma	(60) 3 (5%)	(50) 11 (22%)	(60) 3 (5%)	1 (2%) (50)
Hepatocellular Adenoma Hepatocellular Adenoma, Multiple	` '	11 (22%)	` '	(50)
Hepatocellular Adenoma, Multiple	3 (5%)		3 (5%)	
·		1 (20/.)	3 (3/0)	7 (14%)
Hepatocellular Carcinoma		1 (2%)		1 (2%)
		3 (6%)		4 (8%)
Hepatocellular Carcinoma, Multiple		1 (2%)		
Histiocytic Sarcoma	1 (2%)	4 (8%)	3 (5%)	5 (10%)
Lymphoma Malignant Lymphocytic		4 (8%)		4 (8%)
Lymphoma Malignant Mixed	1 (2%)	4 (8%)	1 (2%)	4 (8%)
Osteosarcoma, Metastatic, Bone			1 (2%)	
Mesentery	(2)	(6)	(0)	(6)
Hemangiosarcoma		1 (17%)		
Histiocytic Sarcoma	1 (50%)	2 (33%)		2 (33%)
Lymphoma Malignant Lymphocytic		1 (17%)		1 (17%)
Lymphoma Malignant Mixed				1 (17%)
Sarcoma, Metastatic, Skin		2 (33%)		2 (33%)
Pancreas	(60)	(49)	(60)	(50)
Lymphoma Malignant Lymphocytic				3 (6%)
Lymphoma Malignant Mixed		1 (2%)		2 (4%)
Sarcoma, Metastatic, Skin				1 (2%)
Salivary Glands	(60)	(49)	(60)	(50)
Lymphoma Malignant Lymphocytic		1 (2%)		2 (4%)
Lymphoma Malignant Mixed		1 (2%)		
Stomach, Forestomach	(60)	(50)	(60)	(50)
Lymphoma Malignant Lymphocytic				1 (2%)
Squamous Cell Papilloma		1 (2%)		
Stomach, Glandular	(60)	(50)	(60)	(50)
Lymphoma Malignant Lymphocytic				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

First Dose M/F: NA / NA

Date Report Requested: 10/16/2014

Time Report Requested: 06:24:54

Lab: BAT

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

B6C3F1 Mouse FEMALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Tooth	(0)	(2)	(0)	(2)
Histiocytic Sarcoma				1 (50%)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(60)	(50)	(60)	(50)
Heart	(60)	(50)	(60)	(50)
Lymphoma Malignant Lymphocytic				2 (4%)
Pericardium, Osteosarcoma, Metastatic, Bone			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(59)	(50)	(60)	(50)
Lymphoma Malignant Lymphocytic		1 (2%)		2 (4%)
Lymphoma Malignant Mixed				1 (2%)
Adrenal Medulla	(59)	(49)	(60)	(50)
Pheochromocytoma Benign	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Islets, Pancreatic	(60)	(49)	(60)	(50)
Adenoma		1 (2%)		2 (4%)
Carcinoma		2 (4%)		
Parathyroid Gland	(52)	(45)	(49)	(46)
Pituitary Gland	(56)	(42)	(56)	(49)
Histiocytic Sarcoma				1 (2%)
Pars Distalis, Adenoma		3 (7%)	1 (2%)	2 (4%)
Pars Intermed, Adenoma	1 (2%)	4 (10%)		2 (4%)
Thyroid Gland	(60)	(50)	(59)	(50)
Bilateral, Follicular Cel, Adenoma				1 (2%)
Follicular Cel, Adenoma	1 (2%)	1 (2%)		
Follicular Cel, Carcinoma				1 (2%)
Lymphoma Malignant Lymphocytic				1 (2%)
Lymphoma Malignant Mixed		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:55

First Dose M/F: NA / NA

B6C3F1 Mouse FEMALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36
GENERAL BODY SYSTEM				
Tissue NOS	(0)	(0)	(1)	(0)
GENITAL SYSTEM				
Clitoral Gland	(59)	(50)	(59)	(48)
Ovary	(60)	(49)	(60)	(49)
Adenoma				1 (2%)
Adenoma, Tubular				1 (2%)
Cystadenoma		1 (2%)		2 (4%)
Granulosa Cell Tumor Benign		1 (2%)		
Histiocytic Sarcoma	1 (2%)	3 (6%)		2 (4%)
Lymphoma Malignant Lymphocytic		3 (6%)		3 (6%)
Lymphoma Malignant Mixed	1 (2%)	2 (4%)		4 (8%)
Sarcoma, Metastatic, Skin				1 (2%)
Uterus	(60)	(49)	(60)	(49)
Histiocytic Sarcoma	2 (3%)	4 (8%)	1 (2%)	3 (6%)
Lymphoma Malignant Lymphocytic				2 (4%)
Lymphoma Malignant Mixed				1 (2%)
Polyp Stromal		1 (2%)	2 (3%)	2 (4%)
HEMATOPOIETIC SYSTEM				
Blood	(0)	(0)	(0)	(1)
Lymphoma Malignant Lymphocytic				1 (100%)
Bone Marrow	(60)	(50)	(60)	(50)
Hemangiosarcoma		2 (4%)		1 (2%)
Hemangiosarcoma, Multiple		1 (2%)		
Histiocytic Sarcoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Lymphoma Malignant Lymphocytic		2 (4%)		1 (2%)
Lymphoma Malignant Mixed		1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

Species/Strain: Mouse/B6C3F1

Pancreatic, Lymphoma Malignant

Pancreatic, Sarcoma, Metastatic, Skin

Lymphocytic

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Time Report Requested: 06:24:55

First Dose M/F: NA / NA

Date Report Requested: 10/16/2014

Lab: BAT

1 (13%)

F				
B6C3F1 Mouse FEMALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Lymph Node	(0)	(13)	(0)	(8)
Axillary, Lymphoma Malignant Lymphocytic				1 (13%)
Axillary, Sarcoma, Metastatic, Skin		1 (8%)		
Hepatocellular Carcinoma, Metastatic, Liver		1 (8%)		
Histiocytic Sarcoma		2 (15%)		
Lumbar, Lymphoma Malignant Lymphocytic				1 (13%)
Lymphoma Malignant Lymphocytic		4 (31%)		
Lymphoma Malignant Mixed		4 (31%)		5 (63%)

		(/		
Renal, Lymphoma Malignant Lymphocytic				1 (13%)
Lymph Node, Bronchial	(0)	(0)	(1)	(1)
Lymphoma Malignant Lymphocytic				1 (100%)
Lymph Node, Mandibular	(60)	(45)	(58)	(47)
Histiocytic Sarcoma		1 (2%)	1 (2%)	1 (2%)
Lymphoma Malignant Lymphocytic		2 (4%)		3 (6%)
Lymphoma Malignant Mixed		4 (9%)	1 (2%)	4 (9%)
Mast Cell Tumor Nos		1 (2%)		
Lymph Node, Mediastinal	(2)	(12)	(4)	(11)
Histiocytic Sarcoma	1 (50%)	1 (8%)	2 (50%)	2 (18%)
Lymphoma Malignant Lymphocytic		4 (33%)		3 (27%)
Lymphoma Malignant Mixed	1 (50%)	6 (50%)	1 (25%)	6 (55%)
Sarcoma, Metastatic, Skin		1 (8%)		
Lymph Node, Mesenteric	(51)	(43)	(60)	(48)
Histiocytic Sarcoma	1 (2%)	2 (5%)	2 (3%)	3 (6%)
Lymphoma Malignant Lymphocytic		3 (7%)		3 (6%)
Lymphoma Malignant Mixed	2 (4%)	8 (19%)	2 (3%)	9 (19%)
Spleen	(60)	(50)	(60)	(50)

1 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Time Report Requested: 06:24:55 First Dose M/F: NA / NA

Date Report Requested: 10/16/2014

Lab: BAT

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

B6C3F1 Mouse FEMALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Hemangiosarcoma		1 (2%)		3 (6%)
Histiocytic Sarcoma		1 (2%)	2 (3%)	
Lymphoma Malignant Lymphocytic		4 (8%)		3 (6%)
Lymphoma Malignant Mixed	1 (2%)	9 (18%)	2 (3%)	6 (12%)
Thymus	(55)	(37)	(59)	(42)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)			
Histiocytic Sarcoma		2 (5%)		
Lymphoma Malignant Lymphocytic		2 (5%)		2 (5%)
Lymphoma Malignant Mixed	1 (2%)	1 (3%)		5 (12%)
Osteosarcoma, Metastatic, Bone			1 (2%)	
INTEGUMENTARY SYSTEM				
Mammary Gland	(60)	(49)	(60)	(49)
Carcinoma	1 (2%)			
Lymphoma Malignant Mixed		1 (2%)		
Skin	(60)	(50)	(60)	(50)
Basal Cell Adenoma			1 (2%)	
Squamous Cell Carcinoma				1 (2%)
Subcut Tiss, Fibrosarcoma		1 (2%)		
Subcut Tiss, Sarcoma		4 (8%)		5 (10%)
MUSCULOSKELETAL SYSTEM				
Bone	(60)	(50)	(60)	(50)
Osteosarcoma				1 (2%)
Vertebra, Osteosarcoma			1 (2%)	
Skeletal Muscle	(2)	(0)	(0)	(0)
NERVOUS SYSTEM				
Brain	(60)	(50)	(60)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:55

First Dose M/F: NA / NA

B6C3F1 Mouse FEMALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Astrocytoma Malignant		1 (2%)		
Histiocytic Sarcoma				1 (2%)
Lymphoma Malignant Lymphocytic		2 (4%)		2 (4%)
Peripheral Nerve	(0)	(1)	(3)	(0)
Spinal Cord	(0)	(1)	(1)	(0)
RESPIRATORY SYSTEM				
Lung	(60)	(50)	(60)	(50)
Alveolar/Bronchiolar Adenoma	3 (5%)	2 (4%)	2 (3%)	4 (8%)
Alveolar/Bronchiolar Carcinoma	1 (2%)	3 (6%)		2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple	2 (3%)			
Hepatocellular Carcinoma, Metastatic, Liver		2 (4%)		
Histiocytic Sarcoma	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Lymphoma Malignant Lymphocytic		2 (4%)		3 (6%)
Lymphoma Malignant Mixed	1 (2%)	2 (4%)		4 (8%)
Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)			
Mediastinum, Lymphoma Malignant Mixed		2 (4%)		
Osteosarcoma, Metastatic, Bone			1 (2%)	
Nose	(60)	(50)	(59)	(50)
Lymphoma Malignant Mixed				1 (2%)
Trachea	(60)	(50)	(59)	(50)
SPECIAL SENSES SYSTEM				
Ear	(0)	(1)	(1)	(1)
Eye	(0)	(1)	(0)	(3)
Harderian Gland	(24)	(22)	(26)	(25)
Adenoma	3 (13%)			2 (8%)
Bilateral, Adenoma				1 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:55

First Dose M/F: NA / NA

B6C3F1 Mouse FEMALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
URINARY SYSTEM				
Kidney	(60)	(50)	(60)	(50)
Histiocytic Sarcoma	1 (2%)	2 (4%)		1 (2%)
Lymphoma Malignant Lymphocytic		3 (6%)		4 (8%)
Lymphoma Malignant Mixed		4 (8%)	1 (2%)	5 (10%)
Osteosarcoma, Metastatic, Bone				1 (2%)
Urinary Bladder	(60)	(49)	(60)	(49)
Histiocytic Sarcoma				1 (2%)
Lymphoma Malignant Lymphocytic		1 (2%)		2 (4%)
SYSTEMIC LESIONS				
Multiple Organ	*(60)	*(50)	*(60)	*(50)
Histiocytic Sarcoma	2 (3%)	5 (10%)	3 (5%)	5 (10%)
Lymphoma Malignant Lymphocytic		5 (10%)		4 (8%)
Lymphoma Malignant Mixed	2 (3%)	9 (18%)	3 (5%)	9 (18%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically

Species/Strain: Mouse/B6C3F1

Test Type: CHRONIC

Route: GAVAGE

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: Scopolamine hydrobromide trihydrate

CAS Number: 6533-68-2

Date Report Requested: 10/16/2014 Time Report Requested: 06:24:55

First Dose M/F: NA / NA

B6C3F1 Mouse FEMALE	0 MG/KG 104/WEEK	0 MG/KG 20%/36M	25 MG/KG104/WEEK	25 MG/KG20%/36M
Tumor Summary for FEMALE				
Total Animals with Primary Neoplasms (b)	19	42	16	41
Total Primary Neoplasms	20	68	17	65
Total Animals with Benign Neoplasms	12	22	10	18
Total Benign Neoplasms	12	28	10	29
Total Animals with Malignant Neoplasms	8	35	7	31
Total Malignant Neoplasms	8	39	7	36
Total Animals with Metastatic Neoplasms	1	4	1	3
Total Metastatic Neoplasms	2	8	4	6
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain - Benign or Malignant		1		
Total Uncertain Neoplasms		1		

^{**} END OF REPORT **

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

^{*} Number of animals with any tissue examined microscopically